Status:
COMPLETED
A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
Lead Sponsor:
Cambridge Health Alliance
Collaborating Sponsors:
Northwestern University
Conditions:
Bipolar Disorder
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine if galantamine augmentaion improves cognition in euthymic bipolar patients. In addition, the effect of galantamine on clinical measures of functioning and psy...
Detailed Description
The study length is 12 to 24 weeks depending on whether patients enter the crossover. Study also involves 3 neuropsychology testings.
Eligibility Criteria
Inclusion
- Age 18-60; DSM-IV diagnosis of bipolar disorder, any subtype; Baseline Mini Mental Status exam above 20; MRS \< 16; MADRS \< 16
Exclusion
- Current substance dependence; serious unstable medical conditions; active suicidal ideation; current DSM-IV for a major mood episodes; history of COPD, epilepsy, cardiac arrhythmia, and peptic ulcer disease; meet DSM-IV criteria for dementia
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00195845
Start Date
April 1 2003
End Date
February 1 2007
Last Update
April 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cambridge Health Alliance
Cambridge, Massachusetts, United States, 02139